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HemodialysisAbstract Hypercalcemia–hyperphosphatemia is an unavoidable consequence of end-stage chronic
kidney disease and common in hemodialytic patients. Calcium carbonate (CaCO3) is one type of
phosphate binder used widely and prescribed in patients undergoing hemodialysis, aiming to con-
trol the levels of calcium and phosphate. These drugs are most effective if taken with meals. This
study aimed to evaluate the use of phosphate binders in hemodialysis patients and the factors that
inﬂuence the success of phosphate binder therapy by experimental studies with retrospective data
collection through the medical records and prospectively through the questionnaire and interviews
with patients. The research was conducted in the Unit Hemodialysis building ﬂoor 8 of Cipto
Mangunkusumo Hospital, Jakarta. The data were collected in a retrospective way for two months
(January–February 2013) and a prospective study in March–April 2013. Patients included were
stage 5 chronic kidney disease patients who underwent hemodialysis in hemodialysis ward of Cipto
Mangunkusumo Hospital. Patients who had data of serum levels at the beginning of the use of
calcium phosphate and the ﬁnal data in 2013 got the phosphate binder therapy.
Results: Ninety six patients with stage 5 chronic kidney disease who underwent hemodialysis had
been using phosphate binder for 3 years in average. Patient evaluation showed that hypocalcemia
was obtained in 23%; normokalemia in 42.7% and hypercalcemia in 34.3%. While the percentage
334 L. Setiani Agus et al.of patients with hipofosfatemia14, 6%, normofosfatemia 32.3% and 53.1% hyperphosphatemia.
Results obtained by the prospective analysis of factors that affect the success of the use of
phosphate binder therapy are related to how the routine use of phosphate binders is made by the
patient. Chi square test showed a signiﬁcance of 0.000 (p< 0.05), the effect of 54%.
Conclusion: We can conclude there are many events happening such as hyperphosphatemia in
hemodialysis patients that use phosphate binders. Monitoring of serum levels of calcium phosphate
in patients with chronic kidney disease undergoing hemodialysis should be performed every month.
Education and the role of clinical staff required to assist compliance and therapeutic efﬁcacy of
phosphate binder are necessary.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Risk of death in patients with chronic kidney disease (CKD) is
much higher than the normal population. Data from the Uni-
ted States Renal Data Systems (USRDS) in 2010, state that the
risk of death in patients with chronic kidney disease was 59%
greater than that in normal population (United States Renal
Data Systems, 2012). The United States Population data
issued by the National Kidney and Urologic Diseases Informa-
tion Clearinghouse (NKUDIC) at the end of 2009 showed that
the prevalence of patients with end-stage renal disease was
1738 per 1 million citizens and 370,274 of them lived on
hemodialysis (United States Renal Data System, 2001). Many
factors contributed to the high risk of death, including: cardio-
vascular disorders, diabetes, hypertension, inﬂammation, dysl-
ipidemia, and bone mineral disorders, one of which is
phosphate and calcium metabolic disorder (Foley et al., 2009).
Mineral and bone disorder is found in the majority of pa-
tients with chronic kidney disease stages 3–5, and is universally
experienced by patients with stage 5 on dialysis. Therefore it is
recommended to start the diagnostic check of stage 3. Thera-
peutic strategies aimed at correcting the disorders, including
low-phosphate diets, and at reducing intestinal phosphate
absorption by using phosphate binders in the drugs. In addi-
tion, stage 5 chronic kidney disease patients were recom-
mended to undergo hemodialysis to improve the dialysis
(PERNEFRI, 2009).
Hyperphosphatemia is common in patients with chronic
kidney disease stage 5. Several studies have shown that in-
creases in serum phosphate are associated with increased mor-
bidity and mortality from cardiovascular disease in the
hemodialysis patient population (Block et al., 2004). Increased
serum phosphate is also involved in the pathogenesis of sec-
ondary hyperparathyroidism (Jorna et al., 2004).
Phosphate binders that contain aluminum and calcium have
been used extensively since 1970, and non-calcium or
aluminum-based agents such as sevelamer hydrochloride and
lanthanum carbonate have recently been available. Its use
increased in current practice, although more expensive, the
potential reduction in the risk of vascular calciﬁcation and
toxicity of therapeutic support for a wider application. To
control hyperphosphatemia, the National Kidney Founda-
tion-Kidney Disease Outcomes Quality Initiative (NKF-KDO-
QI) recommends the use of calcium-based phosphate binders in
patients with chronic kidney disease stages 3 and 4, and both cal-
cium-based and calcium–aluminum binders in patients with
stage 5 CKD and dialysis, but the relative usefulness of
phosphate binding agents available is still controversial.To suppress morbidity and mortality, KDOQI target serum
phosphate levels in CKD patients are 3.5–5.5 mg/dL, and the
multiplication of phosphate and calcium levels is less than
55 mg/dL (National Kidney Foundation, 2003). But this target
was not fully achieved, as evidenced by the high prevalence of
hyperphosphatemia in CKD patients.
Patients in the hemodialysis wardofRSCMgetmost of phos-
phatebindertherapywithcalciumcarbonate(CaCO3).Theuseof
this therapy has been started since patients were diagnosed for
CKDstages 3 and 4. Themost effective use of phosphate binders
iswhen theyare takenwithmeals (NationalKidneyFoundation,
2003). Binding phosphate in the diet thus leaves little for the
absorption of calcium. For comparison, administration of phos-
phatebindersbetweenmeals showedagreater result,asevident in
the decreased intestinal calcium absorption. However, this ther-
apy ispreferred inpatientswithhypocalcemiadespitenormalser-
um phosphate concentrations or lower.
Based on the description above, the researcher tried to per-
form and observe the effect of the use of phosphate binders on
serum levels of calcium phosphate in CKD patients undergo-
ing hemodialysis in the Cipto Mangunkusumo Hospital. This
study is expected to evaluate the therapeutic efﬁcacy of the
use of phosphate binders and the factors that inﬂuence the suc-
cess of the therapy.
2. Method
The research used experimental research design. Data were
collected retrospectively using medical records of patients with
serum levels of calcium phosphate examined at the beginning
of the use of phosphate binders and calcium phosphate serum
levels in 2013. The populations in this study were patients with
chronic kidney disease undergoing routine hemodialysis every
week in the hospital ward of cipto Mangunkusumo Jakarta.
The sample size (n) can be determined by using the formula:
n ¼ Za
2xPQ
d2
ð1Þ
n= sample size; Za= 1.96 (a= 5%); P= proportion: 0.714
(Ozkan and Ulusoy, 2011); Q= 1Pﬁ 0.286; d= 0.1.
Sample data were selected through inclusion and exclusion
criteria which are as follows:
2.1. Inclusion criteria
1. Patients consuming calcium carbonate phosphate binder
(CaCO3).
Table 1 Demographic characteristic patients in hemodialysis
ward.
Characteristics n= 96
Amount Percentage (%)
Gender
Inﬂuence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney 3352. Patients with chronic kidney disease undergoing routine
hemodialysis in RSCM for at least 3 months. Patients
who had laboratory data of serum calcium levels at the
beginning of the use of phosphate and calcium phosphate
serum levels in 2013.
3. Patients who did not have a disorder/disease of bone.Male 57 59.40
Female 39 40.60
Job
House wife 28 29.20
Employee 39 40.60
Student 2 2.10
Civil servants and retired 27 28.10
Age
<30–<40 years 23 24.00
40–<50 years 19 19.80
50–<60 years 32 33.30
60–<70 years 18 18.80
P70 years 4 4.20
Body weight
<40–<50 kg 25 26.00
50–<60 kg 37 38.50
60–<70 kg 20 20.80
P70 kg 14 14.60
Figure 1 Percentage host disease in hemodialysis patients.2.2. Exclusion criteria
1. Subjects who meet the inclusion criteria above will not be
included in this study if not willing to follow the study.
2. Patients who use other types of phosphate binders (other
than CaCO3).
Ethical approval was obtained from the relevant Institu-
tional ethics committee prior to study initiation. Demographic
data include gender, age, weight, occupation and calcium
phosphate serum levels obtained from medical records. As
for the use of old data, factors that affect the success of treat-
ment of patients obtained through the questionnaire and inter-
view research with patients.
2.3. Data collection
Results of the data collection are :
1. Descriptive analysis of patient demographic data and indi-
cations of phosphate binder administration (patient data
include age, sex, body weight, comorbidities and longer
use of phosphate binders).
2. Based on data from the serum levels of calcium phosphate,
calcium levels of patients were grouped into early-ﬁnal cal-
cium levels and phosphate levels into early-end phosphate
levels.
3. Recorded a provision of phosphate binder therapy outcome
given to the patient. Outcome grouped into three sections,
patients with calcium-phosphate levels low, normal and
high.
4. Statistically analyzed the factors that inﬂuence the success
of the use of phosphate binders through the results of ques-
tionnaires and interviews with patients
3. Results and discussion
From the results of the demographic data, gender CKD pa-
tients undergoing hemodialysis in Cipto Mangunkusumo hos-
pital consisted of 59.4% men and 40.6% of female (data
presented in Table 1). The data reported by the National
Health and Nutrition Examination (NHANE) survey showed
that the prevalence of CKD increased from 18.8% to 24.5%
at the age of 60 years or more. Most of the patients included
in this study aged in the range of 50–59 years. This can be
attributed to the physiological condition of the progression
of kidney disease. The older a state of physiological functions
of the body organs the reduced is the kidney function.
In recent years, the two most common causes of increased
prevalence of CKD are diabetes and hypertension incidence
(Ozkan and Ulusoy, 2011). Results of a clinical cohort study
in a group of hemodialysis patients found 86% (n= 2535)
of patients with hypertension. In that group only 30% of them
had blood pressure below normal, 58% do not get adequate
treatment and 12% did not receive treatment (Agarwal et al.,2003). Diabetes is often associated with terminal renal disease,
renal disease patients are 15–23% of patients with diabetes
(Middleton et al., 2006). We can conclude from the results of
this study that hypertension and diabetes are common diseases
in hemodialysis patients (Fig. 1). Our results showed a similar
trend where hypertensive and diabetes are diseases that affect
most patients with CKD hemodialysis (Ozkan and Ulusoy,
2011; Agarwal et al., 2003; Middleton et al., 2006). To control
hyperphosphatemia, National Kidney Foundation-Kidney
Disease Outcomes Quality Initiative (NKF-KDOQI) recom-
mends the use of calcium-based phosphate binders in patients
with CKD stages 3 and 4, and calcium-based and calcium–
aluminum based phosphate binders in patients with stage 5
CKD. From the results of the data obtained, majority of
patients use phosphate binders over a period of 3 years (Fig. 2).
The results of this study show that 22 patients (23%) had
levels under the normal ﬁnal calcium level (hypocalcemia),
duration of use (years)
Figure 2 Use of phosphate binders on the long hemodialysis
patients.
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336 L. Setiani Agus et al.patients who achieved normal calcium levels were 41 patients
(42.7%), whereas 33 patients (34.3%) achieved hypercalcemia
(Fig. 3). The relationship between serum calcium with high
mortality has been shown in several studies (Block et al.,
2004). Because of the relationship of hypercalcemia with mor-
tality, KDOQI recommended that the target serum calcium
levels should be 8.4–9.5 mg/dL. According to the study, hypo-
calcemia trend seen in the group of hemodialysis patients in re-
cent years as a result of decrease in the use of calcimimetic,
phosphate binders without calcium, dialysate with low calcium
levels and calcium intake through food (Hemodialysis Ade-
quacy Work Group, 2006).
Calcium levels less than 9 mg/dL and more than 10 mg/dL
were associated with increased mortality (Miller et al., 2010).
Hypercalcemia can lead to death because of the tendency for
the incidence of arrhythmias, hypertension and vascular calci-
ﬁcation and the tendency to hypocalcemia kejaddian arrhyth-
mias in patients. It can be concluded from the results of this
study in which the incidence of hypocalcemia and hypercalce-
mia still occur in some cases of patients with the percentage of
each 23% and 34.3% (Fig. 3).
On evaluation of the patients’ serum phosphate level assess-
ment it was found that 14 patients (14.6%) were with phos-
phate levels below normal (hypophosphatemia). Patients
undergoing hemodialysis who achieved the target phosphatelevels were 31 (32.3%). As for more than normal phosphate
levels (hyperphosphatemia) there were 51 patients (53.1%).
(Fig. 4) Serum phosphate levels in CKD patients undergoing
hemodialysis should be maintained between 3.3 and 5.5 mg/dl.
Block results of research show the percentage of the popu-
lation for disorders of mineral metabolism in hemodialysis pa-
tients was 17.5%, largely due to the high prevalence of
hyperphosphatemia. Hyperphosphatemia and secondary
hyperparathyroidism directly related to mortality and morbid-
ity with other diseases such as cardiovascular diseases and
bone disorders in patients hemodialysis (Block et al., 2004).
ANOVA statistical test was used to ﬁnd out the relation-
ship of the duration of phosphate binder use with the achieved
levels of calcium and phosphate binders. From the results of
the anova test between calcium and phosphate to the success
of long usage signiﬁcance value, respectively 0.750 and 0.278,
the value is greater than 0.05 and so was declared not signiﬁ-
cant. It can be concluded from this study that there is no rela-
tionship between the success of the inﬂuence of calcium
phosphate levels and the duration of use of phosphate binders
in hemodialysis patients.
To determine the factors that inﬂuence the success of the
use of phosphate binder therapy, researchers conducted a pro-
spective analysis of data through questionnaire and interview
sheet directly to the patient. The questionnaire consisted of
six questions related to the phosphate binder and given to
the same sample of patients with previous retrospective analy-
sis. The questionnaire sheets were analyzed by using the statis-
tical correlation chi-square test, each of the questions was
associated with the successful achievement of therapeutic levels
of calcium and phosphate.
From the results of a prospective analysis conducted by
researchers, it can be concluded that there are factors affecting
the therapeutic efﬁcacy of the use of phosphate binders. These
factors had something to do with how the routine the phos-
phate binders used by the patient. How the routine use of
phosphate binders will affect the success of the phosphate con-
tent of 54%. It is highly associated with mortality prevention
efforts for CKD patients undergoing hemodialysis, in which
it may be associated with secondary hyperparatiroidism and
cardiovascular disease.
Inﬂuence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney 3374. Conclusion
1. The risk of occurrence of hypercalcemia and hyperphos-
phatemia is still more in the majority of patients who
undergo hemodialysis, with respective percentages of
34.4% and 53.1%.
2. From the obtained results of a prospective analysis of fac-
tors that affect the success of the use of phosphate binder
therapy is how the routine use of phosphate binders are
made by the patient. Signiﬁcance test showed 0.000
(p< 0.05), the relationship by 54%.
3. Monitoring of plasma levels of calcium and phosphate in
CKD patients undergoing hemodialysis should be per-
formed every month, in order to prevent the occurrence
of elevated levels of undesirable calcium or phosphate that
may be associated with mortality in CKD patients undergo-
ing hemodialysis.
4. There needs to be further analysis of the factors related to
the management of hypercalcemia and hyperphosphatemia
as analysis for adequate dialysis, dialysate calcium concen-
tration during dialysis patients, as well as the comparison of
the use of other types of phosphate binders.
5. Education and the role of clinical staff to assist patient
compliance and therapeutic efﬁcacy are necessary, such as
providing information for future drug use and the impor-
tance of the patient to take phosphate binders.Acknowledgment
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